Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 8, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

July 31, 2028

Conditions
AML/MDSAcute Myeloid LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

Danvatirsen

Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).

COMBINATION_PRODUCT

Danvatirsen + Venetoclax

"Danvatirsen (AZD9150) is a selective, high-affinity, antisense oligonucleotide inhibitor of signal transducer and activator of transcription 3 (or STAT3).~Venetoclax: Commercially available. Venetoclax is a potent, selective small molecule inhibitor of BCL-2, an anti-apoptotic protein found on some types of cancer cells."

Trial Locations (2)

10467

RECRUITING

Montefiore Medical Center, The Bronx

77030

RECRUITING

M.D. Anderson Cancer Center, Department of Leukemia, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

Flamingo Therapeutics NV

INDUSTRY

lead

Montefiore Medical Center

OTHER